CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset

Authors

  • Annett Maderer Department of Internal Medicine, Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Frederic Fiteni Fellowship Programme Unit, EORTC Headquarters, Brussels, Belgium
  • Erik Tanis Fellowship Programme Unit, EORTC Headquarters, Brussels, Belgium
  • Murielle Mauer Statistics Department, EORTC Headquarters, Brussels, Belgium
  • Thomas Schmitt Department of Internal Medicine, Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Daniela E. Aust Molekulare/Prädiktive Diagnostik, Koordination UCC Tumor- und Normalgewebebank Institut für Pathologie, Dresden, Germany
  • Manfred P. Lutz Caritas Klinikum Saarbrücken, Saarbrücken, Germany
  • Felicitas Roelofson Evangel. Bethesda-Krankenhaus, Essen, Germany
  • Christiane Gog Klinikum der JW Goethe, Universität Frankfurt am Main, Frankfurt, Germany
  • Arndt Weinmann Department of Internal Medicine, Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Claus H. Koehne Department of Oncology and Hematology, Klinikum Oldenburg, European Medical School Oldenburg/Groningen, Carl von Ossietzky University Oldenburg, Oldenburg, Germany
  • Markus Moehler Department of Internal Medicine, Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Thomas Thomaidis Department of Internal Medicine, Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany; Second Department of Gastroenterology, Hygeia Hospital, Athens, Greece

DOI:

https://doi.org/10.1080/0284186X.2021.1959057

Abstract

No Abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2021-11-02

How to Cite

Maderer, A., Fiteni, F., Tanis, E., Mauer, M., Schmitt, T., Aust, D. E., … Thomaidis, T. (2021). CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset. Acta Oncologica, 60(11), 1543–1547. https://doi.org/10.1080/0284186X.2021.1959057

Issue

Vol. 60 No. 11 (2021): Acta Oncologica

Section

Articles